BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Neutral” Rating from JPMorgan Chase & Co.

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a report issued on Monday,Benzinga reports. They presently have a $12.00 price objective on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 14.83% from the company’s previous close.

Other analysts also recently issued research reports about the company. Needham & Company LLC dropped their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Cantor Fitzgerald boosted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wedbush dropped their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $20.80.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $10.45 on Monday. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -5.87 and a beta of 0.55. The company’s 50 day simple moving average is $9.14 and its 200 day simple moving average is $8.45. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.20 EPS. As a group, analysts predict that BioCryst Pharmaceuticals will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares during the last quarter. RA Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $123,452,000. Deerfield Management Company L.P. grew its stake in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after acquiring an additional 7,477,000 shares in the last quarter. State Street Corp grew its stake in shares of BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after acquiring an additional 1,265,773 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of BioCryst Pharmaceuticals by 20.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after acquiring an additional 1,504,120 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.